Jarrow Formulas KSM-66 Ashwagandha 300 mg Review

It's WORSE if you're a first-time buyer who just wants the trial-exact dose in a single capsule (use the single-cap Nutricost 600 mg instead). It's BETTER for three specific audiences: (1) sensitive responders who want to start at 300 mg/day, gauge sedation, then ramp to 600 mg by week 2 without buying a second bottle, (2) AM/PM split-dosers running the Wankhede 2015 / Chandrasekhar 2012 protocol (300 mg twice daily) — Jarrow's 300 mg/cap matches that split exactly, (3) low-dose maintenance users who responded well to higher doses and want to stay on 300 mg/day for indefinite cycling. The dose-per-cap is a feature for the right audience, friction for the wrong one. Pick based on your protocol, not on absolute mg per pill.

Yes — the bottle carries the official KSM-66 logo printed on the FRONT panel, top-right beside the Jarrow wordmark, which is the label's own signal of Ixoreal licensing. Jarrow was founded in 1977, giving it one of the longest operating histories in the supplement industry (the company was acquired by New Mountain Capital in 2020, so it's no longer family-owned — that doesn't affect the KSM-66 supply relationship). Check for the KSM-66 logo on the FRONT panel, next to the Jarrow logo, before opening; if it isn't there, you got a counterfeit listing and should return it.

Week 1-2: 1 cap (300 mg) AM with breakfast — establish baseline tolerance, check for sedation or GI upset. Week 3-4: 2 caps (600 mg) split AM + PM with breakfast and dinner — hit the Wankhede 2015 / Chandrasekhar 2012 trial dose at the trial-exact split. Week 5-8: continue 600 mg/day split or compress to single AM dose based on your sleep response. Re-test cortisol AM, free T, DHEA-S, and SHBG at day 56. If you want to push beyond 600 mg, week 9+ can run 900 mg/day (3 caps) — but the dose-response evidence flattens beyond 600 mg, so additional caps yield diminishing returns. Don't go above 1000 mg/day on standard KSM-66 without specific reason.

If your protocol is 'one capsule with breakfast, done, no titration, no AM/PM split,' then the single-cap Nutricost 600 mg ($14/month) is the simpler trial-exact option — and Double Wood ($22) ships the same Ixoreal extract at the 600 mg dose too, now as a 2-capsule serving, with a public per-batch COA if you want lot-level verification. Jarrow's 300 mg/cap is ONLY the right pick if (a) you want to titrate from 300 to 600 mg over the first 2 weeks, (b) you want to run AM/PM split-dosing (the Wankhede 2015 / Chandrasekhar 2012 protocol), or (c) you want low-dose long-term maintenance at 300 mg/day. For a first-time buyer who just wants the dose in one swallow, the single-cap Nutricost wins. Jarrow's titration granularity is a specific tool for specific protocols.

Comparable but different. Jarrow runs in-house QC with their own analytical labs and a 49-year operating history (founded 1977) — though a GMP certification isn't stated anywhere on this label, so that specific claim can't be verified from the bottle itself. Batch-level testing and supplier docs from Ixoreal are Jarrow's own claims, not label statements. What Jarrow doesn't publish is per-batch COA with consumer lot-lookup the way Double Wood does — Jarrow's QC happens internally and the documentation is available on request via customer service, but it isn't publicly searchable. For audit-driven users tracking per-batch withanolide percentages, Double Wood's public lookup is the upgrade. For users who trust a 49-year brand track record, Jarrow's internal QC documentation is sufficient.

Yes, with caveats. KSM-66 trials in women include Chandrasekhar 2012 and Salve 2019 (both mixed-gender stress trials) and Kelgane 2020 (elderly mixed-gender) showing cortisol reduction + sleep quality improvement at standard doses. The 600 mg/day dose generalises across genders for stress/sleep endpoints. For testosterone-specific effects (Wankhede 2015, men only), women's data is limited — ashwagandha's effect on female testosterone via the cortisol-mediated mechanism is theoretically present but not directly trial-documented at the scale of male data. Avoid if pregnant, breastfeeding, on thyroid meds, or with autoimmune conditions.

Yes — Jarrow's titration flexibility actually makes it a better stack base than single-cap 600 mg bottles. The protocol: Jarrow KSM-66 300 mg AM + Double Wood LJ100 Tongkat 200 mg AM for week 1-2 (low-dose ramp), then add a second Jarrow KSM-66 PM at week 3 to hit 600 mg/day total. This lets you isolate the tongkat-only effect on free T in week 1-2 before adding the cortisol-down lever — useful for diagnosing which lever (SHBG displacement vs HPA-axis suppression) is doing the work in your individual response. Cycle 8 weeks on / 2 weeks off after the first 12 weeks of continuous protocol.

1. [1] Lopresti 2019 (testosterone) PMID 30854916 — A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males. 57 overweight men aged 40-70 took Shoden (21 mg withanolide glycosides a day) or placebo for 8 weeks each in a crossover trial. Testosterone rose 14.7% and DHEA-S 18% more than on placebo; cortisol, fatigue and sexual well-being did not differ. The extract was Shoden, not KSM-66.
2. [2] Wankhede 2015 PMID 26609282 — Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. 600 mg/day KSM-66 consolidated AM dose for 8 weeks in resistance-trained men measured serum testosterone +96 ng/dL vs +18 placebo. Demonstrates the consolidated 600 mg/day protocol — Jarrow can hit this dose at 2 caps/day, just with higher pill-count than the single-cap Nutricost.
3. [3] Chandrasekhar 2012 PMID 23439798 — A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. 600 mg/day KSM-66 for 60 days in chronically stressed adults reduced perceived stress -44% and morning cortisol -27.9% vs placebo. The headline cortisol-suppression evidence — Jarrow's 2 caps/day protocol replicates this dose, with the added flexibility of split AM/PM timing for users who want the PM sedation effect on sleep.
4. [4] Lopresti 2019 (stress) PMID 31517876 — An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. 60 stressed adults took 240 mg of Shoden or placebo once daily for 60 days. Anxiety scores (HAM-A) fell more than on placebo, as did morning cortisol and DHEA-S. Sleep was not an outcome. The extract was Shoden, not KSM-66.
5. [5] Salve 2019 PMID 32021735 — Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. 60 stressed adults took 250 or 600 mg a day of ashwagandha root extract, or a placebo, for 8 weeks. Perceived stress and serum cortisol fell at both doses. Sleep quality improved compared with placebo. Jarrow's 2 caps a day match the 600 mg dose.
6. [6] Kelgane 2020 PMID 32226684 — Efficacy and tolerability of ashwagandha root extract in the elderly for improvement of general well-being and sleep: a prospective, randomized, double-blind, placebo-controlled study. 600 mg/day KSM-66 split AM/PM for 12 weeks in elderly adults improved sleep quality, general well-being, and mental alertness vs placebo. The split-dose elderly evidence — Jarrow's 300 mg/cap matches this split exactly, making it the trial-exact bottle for elderly mixed-gender sleep/well-being protocols.
7. [7] Auddy 2008 — A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: a double-blind, randomized, placebo-controlled study. 125-250 mg/day Sensoril for 60 days reduced serum cortisol -24.2% and raised DHEA-S +32%. Cited here as the KSM-66-vs-Sensoril context: Sensoril matches KSM-66's cortisol effect at lower mg doses but lacks the testosterone evidence base that anchors Jarrow's KSM-66 patent.